Design, Synthesis and Evaluation of Substituted N-(3-Arylpropyl)-9,1 0-dihydro-9-oxoacridine-4-carboxamides as Potent MDR Reversal Agents in Cancer

A novel class of molecules with structure N-(3-arylpropyl)-9,10-dihydro-9-oxoacridine-4-carboxamides (20-29) were designed by generating a pharmacophore for potent MDR reversal activity using phase drug design software. The designed molecules were synthesized by a novel synthesis route and evaluated for their inhibitory effects on the transport activity of P-glycoprotein (P-gp) by standard Hoechst 33342 assay method. Based on the pIC(50) values of ten title compounds screened, three compounds exhibited better activity as compared to Verapamil used as standard.